CTOs on the Move

KalVista Pharmaceuticals

www.kalvista.com

 
KalVista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.kalvista.com
  • 55 Cambridge Pkwy Suite 901E
    Cambridge, MS USA 02142
  • Phone: 857.999.0075

Executives

Name Title Contact Details

Funding

KalVista Pharmaceuticals raised $193.5M on 02/10/2021

Similar Companies

Regeneron

Get in the Ideas Business. At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work together to discover, invent, and develop biopharmaceutical medicines, we`re creating whole new ways of thinking about science, manufacturing and commercialization. And whole new ways of thinking about health. So connect with us. Tell us about you. Learn more about our life-changing medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for more information on how to engage with Regeneron on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. We do not interview candidates on Google Hangouts.

Uromedica

Uromedica, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

InterVenn

InterVenn Biosciences utilizes a proprietary high-throughput glycoproteomic interrogation platform using artificial intelligence and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression.

True North Therapeutics

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.

Revvity

At Revvity, “impossible” is inspiration, and ""can`t be done"" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what`s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With more than $3 billion in revenue and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.